In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drugstore.com

This article was originally published in The Rose Sheet

Executive Summary

Online drugstore expects to acquire 800,000-900,000 new customers in 2002, Bellevue, Wash. company reports during 1fourth quarter and year-end sales and earnings call Jan. 29. Firm notes 225,000 new customers joined the site in Q4, bringing total customer base to 2.4 mil. Net sales for fiscal 2001 reached $145.3 mil., up 32.1% from prior-year period. Fourth quarter sales were $43.5 mil., an increase of 20.2%, company says. Drugstore.com reports a loss of $282.8 mil. for the year, including a $178 mil. restructuring charge, compared to $193 mil. loss a year ago. In Q4, firm recorded loss of $182.9 mil. (including a $163 mil. charge) compared to a loss of $43.2 mil. in 2000 period. Drugstore.com expects to achieve EBITDA profitability by 2003 (2"The Rose Sheet" Jan. 14, 2002, p. 9)...

You may also be interested in...



Drugstore.com Sales Gains, Cost Reductions Expected To Yield Profit By 2003

Online retailer drugstore.com sets $305 mil.-$315 mil. revenue target for 2003 - a level more than double the firm's 2001 sales - as part of an accelerated growth initiative

China-US Divide Deepens On Covid Vaccines, Azar Taiwan Visit

China has shown willingness to go tit-for-tat in its bilateral disputes with the US and the latest comments from US officials show an underlying distrust over clinical data and vaccines safety in China, raising fresh concerns just when collaboration is needed to accelerate availability of the first vaccines in the global pandemic.

Coronavirus Notebook: Middle Ground Pricing As Moderna Reaches 100m Dose US Agreement

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel